Rising Prevalence Of Chronic Diseases Fuels Growth In The Biosimilar Monoclonal Antibodies Market: Critical Driver Shaping the Biosimilar Monoclonal Antibodies Market in 2025

Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts._x000D_
_x000D_
Biosimilar Monoclonal Antibodies Market Size Valuation Forecast: What Will the Market Be Worth by 2025?_x000D_
In recent times, the biosimilar monoclonal antibodies market size has experienced swift expansion. Projected growth estimates suggest a rise from $8.04 billion in 2024 to $9.25 billion in 2025, a compound annual growth rate (CAGR) of 15.1%. Several factors have contributed to this growth during the historical period, including the expiration of patents, increased awareness of biosimilars, government-driven initiatives, heightened investment from pharmaceutical corporations, and the growing acceptance of biosimilars by medical professionals and patients._x000D_
_x000D_
Biosimilar Monoclonal Antibodies Market Size Forecast: What's the Projected Valuation by 2029?_x000D_
In the following years, it's anticipated that the biosimilar monoclonal antibodies market will experience significant growth, ultimately reaching a value of $12.79 billion in 2029, with a compound annual growth rate (CAGR) of 8.5%. This projected growth over the forecast period is due to a variety of factors, including an increase in biologic spending, an expanded biosimilar portfolio, personalized biosimilar therapies, and a growing public curiosity in biosimilars. Other anticipated trends during this period include the development of novel therapies, individualized biosimilars, collaborative ventures and partnerships, the introduction of biosimilar auto injection instruments, and bio-improved iterations._x000D_
_x000D_
View the full report here: _x000D_
https://www.thebusinessresearchcompany.com/report/biosimilar-monoclonal-antibodie-global-market-report_x000D_
_x000D_
What Are the Drivers Transforming the Biosimilar Monoclonal Antibodies Market?_x000D_
The increase in cases of chronic illnesses is predicted to fuel the market for biosimilar monoclonal antibodies. These antibodies are utilized in the management of chronic diseases like cancer, autoimmune disorders, and rheumatoid arthritis. In cancer care, monoclonal antibody biosimilars such as trastuzumab, bevacizumab, and rituximab are commonly used. Additionally, the rate of cancer occurrence continues to rise annually. As per the data released by the Centers for Disease Control and Prevention (CDC), a public health body in the US, in February 2024, an escalating number of US individuals are living with multiple chronic conditions - 42% with two or more, and 12% with five or more. Hence, the surge in chronic illnesses is expected to propel the biosimilar monoclonal antibodies market's expansion._x000D_
_x000D_
Get your free sample here:_x000D_
https://www.thebusinessresearchcompany.com/sample.aspx?id=3412&type=smp_x000D_
_x000D_
What Long-Term Trends Will Define the Future of the Biosimilar Monoclonal Antibodies Market? _x000D_
Key players in the biosimilar monoclonal antibodies market are prioritizing the development of economical biosimilar therapies to stay ahead in the competition. These medical biologics, which closely resemble pre-approved reference monoclonal antibodies, are developed to provide inexpensive treatment alternatives for numerous diseases, such as cancer and autoimmune disorders. Take for example, Pfizer, a pharmaceutical firm based in the U.S., rolled out Abrilada, a biosimilar to AbbVie's Humira (adalimumab), in 2022. Abrilada has shown similar efficacy and safety to its original counterpart while offering substantial cost reductions for both patients and healthcare systems. It also enjoys advantages of a simplified approval process and strong manufacturing capabilities, thus improving patient access to crucial treatments. This development is indicative of a wider industry trend focusing on tackling escalating healthcare expenses without compromising on the quality of therapy options available to patients._x000D_
_x000D_
Which Segments in the Biosimilar Monoclonal Antibodies Market Offer the Most Profit Potential?_x000D_
The biosimilar monoclonal antibodies market covered in this report is segmented - _x000D_
_x000D_
1) By Type: Synthetic Chemicals, Biopharmaceuticals, Other Types_x000D_
2) By Compound: Infliximab, Rituximab, Abciximab, Trastuzumab, Adalimumab, Bevacizumab_x000D_
3) By Application: Chronic & Autoimmune Diseases, Oncology, Other Applications_x000D_
_x000D_
Subsegments:_x000D_
1) By Synthetic Chemicals: Small Molecule Drugs, Chemical Synthesis Products_x000D_
2) By Biopharmaceuticals: Monoclonal Antibodies, Recombinant Proteins, Vaccines, Other Biopharmaceuticals_x000D_
3) By Other Types: Antibody-Drug Conjugates, Fusion Proteins, Biosimilars Of Other Biologics_x000D_
_x000D_
_x000D_
Tailor your insights and customize the full report here:_x000D_
https://www.thebusinessresearchcompany.com/customise?id=3412&type=smp_x000D_
_x000D_
Which Firms Dominate the Biosimilar Monoclonal Antibodies Market by Market Share and Revenue in 2025?_x000D_
Major companies operating in the biosimilar monoclonal antibodies market include Pfizer Inc., Novartis AG, AbbVie Inc., Coherus BioSciences, Biocon Limited, Amgen Inc., Boehringer Ingelheim International GmbH, Celltrion Inc., BioXpress Therapeutics SA, Intas Pharmaceuticals Limited, Genor BioPharma Co. Ltd., BIOCAD, Dr. Reddy's Laboratories Ltd., 3SBio Inc., Reliance Life Sciences, Hisun Pharmaceuticals, Celgen Biopharmaceuticals, Torrent Pharmaceuticals Ltd., Cadila Healthcare Ltd., Shanghai Henlius Biotech Inc., Teva Pharmaceutical Industries Ltd., Alvotech, Xentria Inc., Lazuline Biotech Private Limited, Epygen Biotech Pvt Ltd., Mabpharm Limited, Qilu Pharmaceutical Co. Ltd., Chiatai Tianqing Pharmaceutical Group Co. Ltd., YL Biologics Ltd., Aprogen Biologics, UNDBIO Co Ltd., Samsung Bioepis Co. Ltd., ISU Abxis Corp., Bio-Rad Laboratories Inc. _x000D_
_x000D_
Which Regions Offer the Highest Growth Potential in the Biosimilar Monoclonal Antibodies Market?_x000D_
The countries covered in the biosimilar monoclonal antibodies market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Spain, Canada._x000D_
_x000D_
Purchase the full report today:_x000D_
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=3412_x000D_
_x000D_
"This Report Supports:_x000D_
1.Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions._x000D_
2.Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning._x000D_
3.Policy Makers & Regulators - To track industry developments and align regulatory frameworks._x000D_
4.Consultants & Analysts - To support market entry, expansion strategies, and client advisory work."

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 7882 955267,
Asia: +91 88972 63534,
Americas: +1 310-496-7795 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.